Drug profile

The FDA adverse-event record for Gentamicin + Mometasone + Clotrimazole

274 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Gentamicin + Mometasone + Clotrimazole. See the species affected, top reactions, and outcomes below.

274
adverse-event reports
8.0%
death-coded share
Dog
most-reported species
74
Emesis - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
274
Total Reports
22
Deaths Reported
8.0%
Death Rate

Active Ingredients

Gentamicin + Mometasone + Clotrimazole

Administration Routes

Auricular (Otic)UnknownTopicalOralIntraocularOtherOphthalmic

Species Affected

Dog 261
Cat 13

Most Affected Breeds

Retriever - Labrador 44
Shih Tzu 13
Spaniel - Cocker American 11
Pit Bull 11
Retriever - Golden 11
Crossbred Canine/dog 10
Boxer (German Boxer) 9
Chihuahua 9
Maltese 8
Shepherd Dog - German 8

Most Reported Reactions

Emesis 74
Vomiting 44
Lethargy (see also Central nervous system depression in 'Neurological') 36
Lack of efficacy - NOS 32
Behavioural disorder NOS 25
Diarrhoea 16
Not eating 15
Other abnormal test result NOS 13
Death by euthanasia 13
Anorexia 12
Seizure NOS 12
Lethargy (see also Central nervous system depression in Neurological) 12

Outcome Breakdown

Recovered/Normal
116 (42.3%)
Outcome Unknown
74 (27.0%)
Ongoing
50 (18.2%)
Euthanized
13 (4.7%)
Recovered with Sequela
12 (4.4%)
Died
9 (3.3%)

Gentamicin + Mometasone + Clotrimazole Adverse Event Insights

274 reports name Gentamicin + Mometasone + Clotrimazole; 22 recorded a death outcome (8.0% of reported events, not a population-level mortality rate). Active ingredient: Gentamicin + Mometasone + Clotrimazole. Administration routes: Auricular (Otic), Unknown, Topical, Oral.

By species: Dog (261 reports), Cat (13 reports). By breed: Retriever - Labrador (44), Shih Tzu (13), Spaniel - Cocker American (11).

Leading clinical signs: Emesis (74), Vomiting (44), Lethargy (see also Central nervous system depression in 'Neurological') (36), Lack of efficacy - NOS (32). Outcome, 274 coded reports: Recovered/Normal leads at 42.3%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.